Condensed Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities:
Net Loss	$ (519,722)	$ (439,711)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	10,047	10,776
Amortization of patents	37,957	42,830
Amortization of debt discount	3,065	2,231
Common stock and options issued for compensation, consulting and vendor services	204,156	155,097
Bad debt expense	(78,096)	(36,000)
Loss on Earnings on Medical Joint Venture	124,179
Changes in operating assets and liabilities:
Decrease (Increase) in accounts receivable	205,555	(749,485)
Decrease in inventories	276,157	389,359
Decrease (Increase) to advances to contract manufacturer	171,975	(931,125)
Decrease to prepaid expenses and other current assets	44,257	4,634
Decrease in other assets	18,003	33,338
(Decrease) Increase in accounts payable	(846,004)	434,478
Increase in accrued expenses and other payables	239,519	558,600
Net cash used in operating activities	(108,952)	(524,978)
Cash flows from investing activities:
Purchases of property and equipment	(2,611)	(6,265)
Payment for patent rights	(12,959)	(22,247)
Net cash used in investing activities	(15,570)	(28,512)
Cash flows from financing activities:
Proceeds from exercise of stock options		25,000
Proceeds from issuance of common stock	150,000
Net cash provided by financing activities	150,000	25,000
NET (INCREASE) DECREASE IN CASH AND CASH EQUIVALENTS	25,478	(528,490)
Cash and cash equivalents at beginning of period	96,324	627,082
Cash and cash equivalents at end of period	121,802	98,592
Supplemental disclosure of cash flow information:
Interest paid in cash		$ 23,000